SCHEMBL6779095

SCHEMBL6779095

CCNC(Cc1cc(Cl)c(O)c(Cl)c1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.41
FPR2 P25090 1/20 0.41
TTR P02766 1/20 0.38
FOLH1 Q04609 2/20 0.38
GRN P28799 1/20 0.37
SORT1 Q99523 1/20 0.37
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
MRE11 P49959 1/20 0.35
FTO Q9C0B1 2/20 0.35
HTT P42858 1/20 0.35
CA1 P00915 1/20 0.35
GLA P06280 2/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ABCC2 Q92887 1/20 0.35
ESR1 P03372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6779382 0.98 CA2 (0.41) CA2FPR2TTRFOLH1GRN
SCHEMBL1097052 0.86 CA2 (0.40) CA2FPR2TTRMRE11FTO
SCHEMBL23045322 0.84 CA2 (0.43) CA2FPR2TTRFOLH1AKR1C2
SCHEMBL23045324 0.84 CA2 (0.43) CA2FPR2TTRFOLH1AKR1C2
SCHEMBL5144526 0.81 LMNA (0.50) CA2FPR2FOLH1FTOCA1
SCHEMBL5144531 0.81 LMNA (0.50) CA2FPR2FOLH1FTOCA1
SCHEMBL29855078 0.78 PPARG (0.50) CA2FOLH1GRNSORT1GAA
SCHEMBL3311174 0.77 ADRB2 (0.43) AKR1C2
SCHEMBL11134765 0.76 CTSL (0.50) FPR2FOLH1
SCHEMBL4490755 0.76 MRE11 (0.43) CA2FPR2MRE11HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed